GlassScriptPhysician profile
Jennifer C Waters
NPI 1922196526
$3,842.10
in general payments reported to CMS, 2019-2025
26 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $273 · 2022: $246 · 2023: $636 · 2024: $1,236 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.60 | 2023-2025 | |
| Novo Nordisk INC | $724.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $503.00 | 2022-2025 | Auvelity |
| Pfizer INC. | $370.90 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.06 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $210.74 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $208.09 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $165.42 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $104.47 | 2024-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $55.47 | 2024-2025 | Gvoke Hypopen |
| Medtronic, INC. | $52.63 | 2023-2025 | Inceptiv, Minimed 770g |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.12 | 2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.99 | 2024-2025 | Rexulti |
| Philips North America LLC | $42.24 | 2024-2025 | Ecc Solutions, (Ck7) Extended Holter, (Ck4) Mcot |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.62 | 2022-2023 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.21 | 2023-2024 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $33.64 | 2024 | Voquezna |
| Boston Scientific Corporation | $33.13 | 2024 | |
| Glaxosmithkline, LLC. | $21.44 | 2022 | |
| Astellas Pharma US INC | $18.60 | 2021 | |
| Genentech USA, INC. | $17.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.77 | 2021 | |
| Merck Sharp & Dohme LLC | $15.66 | 2024 | Verquvo |
| Inspire Medical Systems, INC. | $14.61 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $13.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.